Pyridinylquinoxalines and pyridinylpyridopyrazines as lead compounds for novel p38α mitogen-activated protein kinase inhibitors

Journal of Medicinal Chemistry

Volumn 53, Issue 3, 2010, Pages 1128-1137

  Koch, Pierre ^a   Jahns, Hartmut ^a   Schattel, Verena ^a   Goettert, Marcia ^a   Laufer, Stefan ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 DICARBONYL DERIVATIVE; 2(3) (4 FLUOROPHENYL) 3 (2) (PYRIDIN 4 YL)QUINOXALINE; 2(3) (4 FLUOROPHENYL) 3(2) (PYRIDIN 4 YL)PYRIDOPYRAZINE; AMINOPYRIDINE DERIVATIVE; LEAD; MITOGEN ACTIVATED PROTEIN KINASE 14; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PHENYLENEDIAMINE DERIVATIVE; PYRAZINE DERIVATIVE; QUINOXALINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; BIOLOGICAL ACTIVITY; CHEMICAL STRUCTURE; ENZYME INHIBITION; MICROWAVE IRRADIATION; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

HUMANS; MODELS, CHEMICAL; MOLECULAR STRUCTURE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN KINASE INHIBITORS; PYRAZINES; PYRIDINES; QUINOXALINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77249141072     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm901392x     Document Type: Article

References (22)

1. Chen, Z.; Gibson, T. B.; Robinson, F.; Silvestro, L.; Pearson, G.; Xu, B.; Wright, A.; Vanderbilt, C.; Cobb, M. H. MAP kinases. Chem. Rev. 2001, 101, 2449-2476.
2. Kumar, S.; Boehm, J.; Lee, J. C. p38 MAP kinases: Key signalling molecules as therapeutic targets for inflammatory diseases. Nat. Rev. Drug Discovery 2003, 2, 717-726.
3. Kaminska, B. MAPK signalling pathways as molecular targets for anti-inflammatory therapy: From molecular mechanisms to therapeutic benefits. Biochim. Biophys. Acta 2005, 1754, 253-262.
4. Koch, P.; Baeuerlein, C.; Jank, H.; Laufer, S. Targeting the ribose and phosphate binding site of p38 mitogen-activated protein (MAP) kinase: Synthesis and biological testing of 2-alkylsulfanyl-, 4(5)-aryl-, 5(4)-heteroaryl- substituted imidazoles. J. Med. Chem. 2008, 51, 5630-5640.
5. Laufer, S.; Koch, P. Towards the improvement of the synthesis of novel 4(5)-aryl-5(4)-heteroaryl-2-thio-substituted imidazoles and their p38MAPkinase inhibitory activity. Org. Biomol. Chem. 2008, 6, 437-439.
6. Wagner, G.; Laufer, S. Small molecular anti-cykotine agents. Med. Res. Rev. 2006, 26, 1-62.
7. Peifer, C.; Kinkel, K.; Abadleh, M.; Schollmeyer, D.; Laufer, S. From five- to six-membered rings: 3,4-Diarylquinolinone as lead for novelp38MAPkinase inhibitors. J. Med. Chem. 2007, 50, 1213-1221.
8. Kolb, H. C.; Finn, M. G.; Sharpless, K. B. Click chemistry: Diverse chemical function from a few good reactions. Angew. Chem., Int. Ed. 2001, 40, 2004-2021.
9. Li, Z.; Li, W.; Sun, Y.; Huang, H.; Ouyang, P. Room temperature facile synthesis of quinoxalines catalyzed by amidosulfonic acid. J. Heterocycl. Chem. 2008, 45, 285-288.
10. More, S. V.; Sastry, M. N. V.; Wang, C. C.; Yao, C. F. Molecular iodine. A powerful catalyst for the easy and efficient synthesis of quinoxalines. Tetrahedron Lett. 2005, 46, 6345-6348.
11. More, S. V.; Sastry, M. N. V.; Yao, C. F. Cerium(IV) ammonium nitrate (CAN) as a catalyst in tap water: A simple, efficient and green approach to the synthesis of quinoxalines. Green Chem. 2006, 8, 91-95.
12. Zhao, Z.; Wisnoski, D. D.; Wolkenberg, S. E.; Leister, W. H.; Wang, Y.; Lindsley, C. W. General microwave-assisted protocols for the expedient synthesis of quinoxalines and heterocyclic pyrazines. Tetrahedron Lett. 2004, 45, 4873-4876.
13. Jahns, H.; Koch, P.; Schollmeyer, D.; Laufer, S. 3-(4-Fluorophenyl)-6- methoxy-2-(4-pyridyl)quinoxaline. Acta Crystallogr. 2009, E65, o1626.
14. Wolfe, J. P.; Wagaw, S.; Marcoux, J. F.; Buchwald, S. L. Rational development of practical catalysts for aromatic carbon-nitrogen bond formation. Acc. Chem. Res. 1998, 31, 805-818.
15. Koch, P.; Schollmeyer, D.; Laufer, S. 3-(4-Fluorophenyl)-2-(4-pyridyl) pyrido[2,3-b]pyrazine. Acta Crystallogr. 2009, E65, o2546.
16. Koch, P.; Schollmeyer, D.; Laufer, S. 2-(4-Fluorophenyl)-3-(4-pyridyl) pyrido[2,3-b]pyrazine. Acta Crystallogr. 2009, E65, o2512.
17. Koch, P.; Schollmeyer, D.; Laufer, S. 4-[3-(4-Fluorophenyl)quinoxalin-2- yl]-N-isopropylpyridin-2-amine. Acta Crystallogr. 2009, E65, o1344.
18. Laufer, S.; Thuma, S.; Peifer, C.; Greim, C.; Herweh, Y.; Albrecht, A.; Dehner, F. An immunosorbent, nonradioactive p38 MAP kinase assay comparable to standard radioactive liquid-phase assays. Anal. Biochem. 2005, 344, 135-137.
19. Peifer, C.; Luik, S.; Thuma, S.; Herweh, Y.; Laufer, S. Development and optimization of a non-radioactive JNK3 assay. Comb. Chem. High Throughput Screening 2006, 9, 613-618.
20. Jaguar, version 7.5; Schroedinger, LLC: New York, 2008.
21. Schroedinger Suite 2008, Induced Fit Docking Protocol. Glide, version 5.0; Schroedinger, LLC: New York, 2005.
22. Golebiowski, A.; Townes, J. A.; Laufersweiler, M. J.; Brugel, T. A.; Clark, M. P.; Clark, C. M.; Djung, J. F.; Laughlin, S. K.; Sabat, M. P.; Bookland, R. G.; VanRens, J. C.; De, B.; Hsieh, L. C.; Janusz, M. J.; Walter, R. L.; Webster, M. E.; Mekel, M. J. The development of monocyclic pyrazolone based cytokine synthesis inhibitors. Bioorg. Med. Chem. Lett. 2005, 15, 2285-2289.